Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study

Clinical Therapeutics

Volumn 32, Issue 7, 2010, Pages 1357-1370

  Pérez, Concepción ^a   Navarro, Ana ^b   Saldaña, María T ^c   Masramón, Xavier ^d   Rejas, Javier ^e  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Primary Care Health Centre Puerta del ngel   (Spain)

^c Primary Care Health Centre Raices   (Spain)

^d European Biometrics Institute   (Spain)

^e PFIZER INC   (United States)

Author keywords

Costs; Gabapentin; Head to head comparison; Neuropathic pain; Patient reported outcomes; Pregabalin; Therapeutic dose

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANXIETY; ARTICLE; CERVICOBRACHIAL NEURALGIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIABETIC NEUROPATHY; FEMALE; HEALTH CARE COST; HUMAN; MALE; MEDICAL PRACTICE; NEUROPATHIC PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; POSTHERPETIC NEURALGIA; PRIMARY MEDICAL CARE; QUESTIONNAIRE; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIGEMINUS NEURALGIA; VISUAL ANALOG SCALE;

AGED; AMINES; ANALGESICS; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; CYCLOHEXANECARBOXYLIC ACIDS; DRUG COSTS; EFFICIENCY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PRIMARY HEALTH CARE;

EID: 77955258979     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.07.014     Document Type: Article

References (53)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008, 70:1630-1635.
2. Gilron I, Watson CP, Cahill CM, Moulin DE Neuropathic pain: A practical guide for the clinician. CMAJ 2006, 175:265-275.
3. Berger A, Dukes EM, Oster G Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004, 5:143-149.
4. Lachaine J, Gordon A, Choinière M, et al. Painful neuropathic disorders: An analysis of the Régie de l'Assurance Maladie du Québec database. Pain Res Manag 2007, 12:31-37.
5. McWilliams LA, Goodwin RD, Cox BJ Depression and anxiety associated with three pain conditions: Results from a nationally representative sample. Pain 2004, 111:77-83.
6. Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005, 30:374-385.
7. Argoff CE The coexistence of neuropathic pain, sleep, and psychiatric disorders: A novel treatment approach. Clin J Pain 2007, 23:15-22.
8. Gallagher RM, Verma S Managing pain and comorbid depression: A public health challenge. Semin Clin Neuropsychiatry 1999, 4:203-220.
9. Smith MT, Haythornthwaite JA How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev 2004, 8:119-132.
10. Schmader KE Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002, 18:350-354.
11. Smith BH, Torrance N, Bennett MI, Lee AJ Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007, 23:143-149.
12. Gálvez R, Marsal C, Vidal J, et al. Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions. Eur J Pain 2007, 11:244-255.
13. McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: Results from a cross-sectional survey. Eur J Pain 2006, 10:127-135.
14. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: The patients' perspectives. J Pain 2006, 7:892-900.
15. Currie CJ, Poole CD, Woehl A, et al. The financial costs of healthcare treatment for people with type 1 or type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med 2007, 24:187-194.
16. Rodríguez MJ, García AJ A registry of the aetiology and costs of neuropathic pain in pain clinics: Results of the registry of etiologies and costs (REC) in neuropathic pain disorders study. Clin Drug Investig 2007, 27:771-782. Investigators of Collaborative Study.
17. Gallagher RM Neuropathic pain: The global challenge. Pain Med 2004, 5(Suppl 1):S1-S2.
18. Harden N, Cohen M Unmet needs in the management of neuropathic pain. J Pain Symptom Manage 2003, 25(Suppl 5):S12-S17.
19. Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006, 13:1153-1169. EFNS Task Force.
20. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007, 12:13-21. Canadian Pain Society.
21. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005, 118:289-305.
22. Gilron I Gabapentin and pregabalin for chronic neuropathic and early post-surgical pain: Current evidence and future directions. Curr Opin Anaesthesiol 2007, 20:456-472.
23. Guay DR Pregabalin in neuropathic pain: A more "pharmaceutically elegant" gabapentin?. Am J Geriatr Pharmacother 2005, 3:274-287.
24. Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A 2008, 105:3628-3633.
25. Gore M, Sadosky A, Tai KS, Stacey B A retrospective evaluation of the use of gabapentin and pregabalin in patients with post-herpetic neuralgia in usual-care settings. Clin Ther 2007, 29:1655-1670.
26. Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: A quantitative systematic review. PLoS Med 2005, 2:e164.
27. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009, (3):CD007076.
28. Tarride JE, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: A Canadian perspective. Clin Ther 2006, 28:1922-1934.
29. Rodríguez MJ, Díaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007, 23:2585-2596.
30. O'Connor AB, Noyes K, Holloway RG A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc 2007, 55:1176-1184.
31. Navarro A, Saldaña MT, Pérez C, et al. Patient-reported-outcomes in subjects with neuropathic pain receiving pregabalin: Evidence from the medical practice in primary care settings. Pain Med 2010, 11:719-731.
32. Saldaña MT, Navarro A, Pérez C, et al. Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: Evidence from medical practice in primary care settings. Rheumatol Int 2010, 30:1005-1015.
33. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005, 114:29-36.
34. Perez C, Galvez R, Huelves S, et al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes 2007, 5:66-75.
35. Melzack R The short-form McGill Pain Questionnaire. Pain 1987, 30:191-197.
36. Zigmond AS, Snaith RP The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
37. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The EuroQol Group.
38. Sheehan DV, Harnett-Sheehan K, Raj BA The measurement of disability. Int Clin Psychopharmacol 1996, 11(Suppl 3):S89-S95.
39. Hays RD, Stewart AL Sleep measures. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach 1992, 235-259. Duke University Press, Durham, NC. A.L. Stewart, J.E. Ware (Eds.).
40. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004, 108:248-257.
41. Rejas J, Ribera MV, Ruiz M, Masrramón X Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. Eur J Pain 2007, 11:329-340.
42. Stewart WF, Lipton RB, Simon D Work-related disability: Results from the American migraine study. Cephalalgia 1996, 16:231-238. discussion.
43. Stewart WF, Lipton RB, Simon D Work-related disability: Results from the American migraine study. Cephalalgia 1996, 16:215.
44. Spanish Pharmaceutical Drug Catalogue 2006, [in Spanish], General Council of the Official Pharmaceutical Colleges of Spain, Madrid, Spain.
45. Centre for studying Health Economics and Social Policy, Health costs database, version 2.2. Accessed February 10, 2006. http://www.soikos.com.
46. Labour cost quarterly survey National Institute of Statistics, Accessed February 10, 2006. http://www.ine.es/daco/daco42/etcl/etcl0405.pdf.
47. 2 test. Suppl J Royal Stat Soc 1934, 1:217-235.
48. Brooks R EuroQoL: The current state of play. Health Policy 1996, 37:53-72.
49. Lydiard R, Perera P, Batzar E, Clary CM From the bench to the trench: A comparison of sertraline treatment of major depression in clinical and research patient samples. Prim Care Companion J Clin Psychiatry 1999, 1:154-162.
50. Díaz-Marsá M, nchez S, Rico-Villademoros F Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: A multicenter, prospective, and naturalistic study. J Clin Psychiatry 2009, 70:509-517. ZIP-IIG-79 Study Group.
51. Backonja M, Glanzman RL Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003, 25:81-104.
52. van Seventer R, Sadosky A, Lucero M, Dukes E A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006, 35:132-137.
53. Gore M, Dukes E, Rowbotham DJ, et al. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain 2007, 11:652-664.